Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population.

Kaplan DJ, Boorjian SA, Ruth K, Egleston BL, Chen DY, Viterbo R, Uzzo RG, Buyyounouski MK, Raysor S, Giri VN.

BJU Int. 2010 Feb;105(3):334-7. doi: 10.1111/j.1464-410X.2009.08793.x. Epub 2009 Aug 25.

PMID:
19709072
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population.

Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, Troyer DA, Leach RJ, Thompson IM.

Urology. 2006 Dec;68(6):1152-5.

PMID:
17169636
[PubMed - indexed for MEDLINE]
3.

Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.

Hernandez DJ, Han M, Humphreys EB, Mangold LA, Taneja SS, Childs SJ, Bartsch G, Partin AW.

BJU Int. 2009 Mar;103(5):609-14. doi: 10.1111/j.1464-410X.2008.08127.x. Epub 2008 Oct 24.

PMID:
19007374
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.

Uzzo RG, Pinover WH, Horwitz EM, Parlanti A, Mazzoni S, Raysor S, Mirchandani I, Greenberg RE, Pollack A, Hanks GE, Watkins-Bruner D.

Urology. 2003 Apr;61(4):754-9.

PMID:
12670560
[PubMed - indexed for MEDLINE]
5.

Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men.

Giri VN, Egleston B, Ruth K, Uzzo RG, Chen DY, Buyyounouski M, Raysor S, Hooker S, Torres JB, Ramike T, Mastalski K, Kim TY, Kittles R.

Cancer Prev Res (Phila). 2009 Mar;2(3):244-50. doi: 10.1158/1940-6207.CAPR-08-0150. Epub 2009 Feb 24.

PMID:
19240249
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection.

Hughes L, Zhu F, Ross E, Gross L, Uzzo RG, Chen DY, Viterbo R, Rebbeck TR, Giri VN.

Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):53-60. doi: 10.1158/1055-9965.EPI-11-0727. Epub 2011 Dec 5.

PMID:
22144497
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.

Pepe P, Aragona F.

Can J Urol. 2013 Feb;20(1):6620-4.

PMID:
23433132
[PubMed - indexed for MEDLINE]
8.

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome.

Vickers AJ, Sjoberg DD, Ankerst DP, Tangen CM, Goodman PJ, Thompson IM Jr.

Cancer. 2013 Aug 15;119(16):3007-11. doi: 10.1002/cncr.28114. Epub 2013 May 29.

PMID:
23720006
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr.

J Natl Cancer Inst. 2006 Apr 19;98(8):529-34.

PMID:
16622122
[PubMed - indexed for MEDLINE]
Free Article
10.

External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.

Zhu Y, Wang JY, Shen YJ, Dai B, Ma CG, Xiao WJ, Lin GW, Yao XD, Zhang SL, Ye DW.

Asian J Androl. 2012 Sep;14(5):738-44. doi: 10.1038/aja.2012.28. Epub 2012 May 7.

PMID:
22561907
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.

Chang BL, Hughes L, Chen DY, Gross L, Ruth K, Giri VN.

BJU Int. 2014 May;113(5b):E150-6. doi: 10.1111/bju.12264. Epub 2013 Aug 13.

PMID:
23937305
[PubMed - indexed for MEDLINE]
12.

Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate.

Cross CK, Shultz D, Malkowicz SB, Huang WC, Whittington R, Tomaszewski JE, Renshaw AA, Richie JP, D'Amico AV.

J Clin Oncol. 2002 Jun 15;20(12):2863-8.

PMID:
12065563
[PubMed - indexed for MEDLINE]
13.

PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.

Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr.

Urology. 2009 May;73(5):935-9. doi: 10.1016/j.urology.2008.09.079. Epub 2009 Mar 28.

PMID:
19328538
[PubMed - indexed for MEDLINE]
14.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Clin Oncol. 2007 Jul 20;25(21):3076-81.

PMID:
17634486
[PubMed - indexed for MEDLINE]
15.

The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.

Ankerst DP, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, Partin AW, Chan DW, Sokoll L, Kagan J, Wei JT, Thompson IM.

J Urol. 2013 Jul;190(1):70-6. doi: 10.1016/j.juro.2012.12.108. Epub 2013 Jan 9.

PMID:
23313212
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.

Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW.

Eur Urol. 2013 Apr;63(4):627-33. doi: 10.1016/j.eururo.2012.07.029. Epub 2012 Jul 20.

PMID:
22841675
[PubMed - indexed for MEDLINE]
17.

Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone.

Crawford ED, Moul JW, Rove KO, Pettaway CA, Lamerato LE, Hughes A.

BJU Int. 2011 Dec;108(11):1743-9. doi: 10.1111/j.1464-410X.2011.10224.x. Epub 2011 Jun 28.

PMID:
21711431
[PubMed - indexed for MEDLINE]
18.

Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, Sokoll LJ, Sanda MG, Wei JT, Leach RJ, Thompson IM.

Urology. 2014 Jun;83(6):1362-7. doi: 10.1016/j.urology.2014.02.035.

PMID:
24862395
[PubMed - indexed for MEDLINE]
19.

Prostate-specific antigen concentration in young men: new estimates and review of the literature.

Sutcliffe S, Pakpahan R, Sokoll LJ, Elliott DJ, Nevin RL, Cersovsky SB, Walsh PC, Platz EA.

BJU Int. 2012 Dec;110(11):1627-35. doi: 10.1111/j.1464-410X.2012.11111.x. Epub 2012 Apr 13. Review.

PMID:
22502603
[PubMed - indexed for MEDLINE]
20.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

PMID:
23588999
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk